摘要
目的探讨HBeAg阳性与HBeAg阴性慢性重型乙型肝炎患者的临床特征。方法对95例慢性重型乙型肝炎患者的临床资料、肝功能、肝纤维化指标、HBVDNA载量及并发症发生率进行回顾性分析。结果95例患者中，HBeAg阳性41例（43％），HBeAg阴性54例（57％）。HBeAg阳性组与HBeAg阴性组平均发病年龄，ALB、TB、CHE、肝纤维化指标及肝衰竭并发症发生率差异无统计学意义（P〉0．05）。HBeAg阴性患者的ALT、AST分别为（400．37±413．59）U／L和（578．14±600．23）U／L，高于阳性患者的（198．25±215．37）u／L和（254．78±269．16）U／L（P〈0．05）。HBeAg阳性患者的HBVDNA载量为（6．17×10^6±8．24×10^1）copies／ml高于阴性患者的（2．39×10^5±6．75×10^1）copies／ml，两组间具有显著差异（P〈0．05）。另外HBeAg阳性患者的左肝前后径及右肝厚度分别为（65．12±12．43）mm及（95．37±12．69）mm，均高于阴性患者的（56．78±11．04）mm和（89．34±9．23）mm（P〈0．05）。结论HBeAg阴性慢性重型乙型肝炎患者与HBeAg阳性患者相比在较低的HBVDNA载量下，仍引起较高的肝损伤和较大幅度的肝脏萎缩。
Objective To investigate the clinical characteristics in chronic severe hepatitis B patients with HbeAg-positive and HbeAg-negative. Methods A total of 95 chronic severe hepatitis B cases were retrospectively analyzed. The clinical information, hepatic function, hepatic fibrosis and HBV DNA in HBeAg-negative and HBeAg- positive groups were analyzed. Results Of the 95 cases, 54 （57%） were HBeAg-negative and 41 （ 43% ） were HBeAg-positive. No significant differences were found on age, ALB, TB, CHE, indexes of hepatic fibrosis and the ratio of complications between HBeAg-negative group and HBeAg-positive group. Compared with HBeAg-positive group, there were significantly higher levels of ALT [ （ 198. 25 ±215.37 ） U/L vs（ 400. 37 ±413.59 ） U/L ], AST[ （ 254. 78 ±269. 16）U/L vs（578.14 ±600.23） U/L] and lower level of HBV DNA[ （6. 17 × 10^6 ± 8.24 × 10^1 ） copies/ml vs （2. 39 × 10^5 ± 6. 75 × 10^1 ） copies/ml ] in HBeAg-negative group（ P 〈 0. 05 ）. The anteroposterior diameter of the left liver and the thickness of fight liver were（ 65.12± 12.43 ）mm and（ 95.37±12. 69）mm in the HBeAg positive fatal chronic severe hepatitis B before the terminal phase, vs （ 56.78 ± 11.04 ） mm and （ 89. 34 ± 9. 23 ）mm in the HBeAg negative group, and the former is longer than the later（ P 〈 0. 05 ）. Conclusion Tissue injury is more serious and the level of HBV DNA is lower in HBeAg-negative patients than HBeAg-positive patients. Liver size of HBeAg negative group reduces more significantly than HBeAg positive group before terminal phase.
出处
《中国基层医药》
CAS
2010年第1期50-52,共3页
Chinese Journal of Primary Medicine and Pharmacy
